Total Payments
$808,362
2024 Payments
$101,162
Companies
27
Transactions
504
Medicare Patients
925
Medicare Billing
$105,104
Payment Breakdown by Category
Consulting$625,943 (77.4%)
Travel$86,281 (10.7%)
Research$46,673 (5.8%)
Other$40,355 (5.0%)
Food & Beverage$9,110 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $625,943 | 222 | 77.4% |
| Travel and Lodging | $86,281 | 94 | 10.7% |
| Unspecified | $46,673 | 11 | 5.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $40,355 | 22 | 5.0% |
| Food and Beverage | $9,110 | 155 | 1.1% |
Payments by Type
General
$761,689
493 transactions
Research
$46,673
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $224,370 | 132 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $72,611 | 42 | $0 (2024) |
| Eli Lilly and Company | $57,128 | 12 | $0 (2024) |
| AstraZeneca UK Limited | $48,065 | 22 | $0 (2024) |
| Genentech USA, Inc. | $33,688 | 30 | $0 (2024) |
| BeiGene USA, Inc. | $32,890 | 21 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $29,541 | 39 | $0 (2023) |
| Janssen Global Services, LLC | $26,141 | 25 | $0 (2023) |
| Secura Bio, Inc. | $25,500 | 2 | $0 (2022) |
| Celgene Corporation | $25,008 | 10 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $101,162 | 65 | ABBVIE INC. ($25,797) |
| 2023 | $157,621 | 78 | Eli Lilly and Company ($37,378) |
| 2022 | $124,975 | 53 | ABBVIE INC. ($39,760) |
| 2021 | $78,369 | 52 | AstraZeneca UK Limited ($10,960) |
| 2020 | $104,997 | 45 | AbbVie Inc. ($25,236) |
| 2019 | $87,832 | 82 | AbbVie, Inc. ($35,476) |
| 2018 | $110,563 | 101 | AbbVie, Inc. ($48,630) |
| 2017 | $42,844 | 28 | AbbVie, Inc. ($15,013) |
All Payment Transactions
504 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $4,100.00 | General |
| 12/09/2024 | Eli Lilly and Company | JAYPIRCA (Drug) | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| Category: Oncology | ||||||
| 12/09/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $135.00 | General |
| 12/07/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $118.88 | General |
| Category: Oncology | ||||||
| 12/06/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $55.71 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $15.00 | General |
| 12/06/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $12.86 | General |
| Category: ONCOLOGY | ||||||
| 11/04/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,150.00 | General |
| Category: Oncology | ||||||
| 10/24/2024 | AstraZeneca UK Limited | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $1,370.00 | General |
| Category: Oncology | ||||||
| 10/19/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $29.43 | General |
| Category: ONCOLOGY | ||||||
| 10/14/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,027.50 | General |
| 10/02/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $110.07 | General |
| Category: Oncology | ||||||
| 09/26/2024 | AstraZeneca UK Limited | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $60.17 | General |
| Category: Oncology | ||||||
| 09/25/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Consulting Fee | Cash or cash equivalent | $2,437.50 | General |
| Category: Oncology | ||||||
| 09/25/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $80.21 | General |
| Category: Oncology | ||||||
| 09/24/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Travel and Lodging | In-kind items and services | $217.31 | General |
| Category: Oncology | ||||||
| 09/18/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| 09/18/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $29.88 | General |
| 08/21/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| Category: ONCOLOGY | ||||||
| 08/19/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $1,370.00 | General |
| 08/15/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,370.00 | General |
| 08/13/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $5,600.00 | General |
| 07/29/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $1,370.00 | General |
| 07/16/2024 | BeiGene Switzerland GmbH | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: Oncology | ||||||
| 07/16/2024 | BeiGene Switzerland GmbH | BRUKINSA (Drug) | Travel and Lodging | Cash or cash equivalent | $160.96 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3 OPEN-LABEL RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) | Eli Lilly and Company | $30,583 | 2 |
| CC-5013-CLL-010 | Celgene Corporation | $4,267 | 1 |
| A PROSPECTIVE, OPEN-LABEL, MULTICENTER RANDOMIZED PHASE III TRIAL TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF OBINUTUZUMAB AND VENETOCLAX GDC-0199ABT-199 VERSUS OBINUTUZUMAB AND CHLORAMBUCIL IN PREVIOUSLY UNTREATED PATIENTS WITH CLL AND COEXISTING MEDICAL CONDITIONS | F. Hoffmann-La Roche AG | $4,077 | 1 |
| Celgene - Connect CLL | Celgene Corporation | $2,533 | 1 |
| A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT | Takeda Pharmaceuticals U.S.A., Inc. | $2,200 | 1 |
| UTXTGR205 | TG Therapeutics, Inc. | $15.58 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 240 | 299 | $150,617 | $26,178 |
| 2022 | 4 | 217 | 284 | $138,788 | $25,791 |
| 2021 | 6 | 244 | 372 | $160,001 | $35,885 |
| 2020 | 6 | 224 | 265 | $73,644 | $17,250 |
Total Patients
925
Total Services
1,220
Medicare Billing
$105,104
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 178 | 219 | $89,407 | $16,433 | 18.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 43 | 61 | $44,502 | $7,069 | 15.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 19 | 19 | $16,708 | $2,677 | 16.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 149 | 194 | $77,558 | $14,914 | 19.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 37 | 54 | $38,506 | $6,718 | 17.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 18 | 18 | $15,542 | $2,619 | 16.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 13 | 18 | $7,182 | $1,540 | 21.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 121 | 168 | $56,952 | $13,423 | 23.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 45 | 71 | $43,523 | $9,002 | 20.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 23 | 75 | $29,925 | $6,724 | 22.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 18 | 18 | $13,518 | $3,129 | 23.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 12 | 12 | $8,799 | $1,848 | 21.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 25 | 28 | $7,284 | $1,759 | 24.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 49 | 68 | $18,748 | $4,256 | 22.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 21 | 21 | $12,558 | $3,088 | 24.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 39 | 44 | $10,318 | $3,026 | 29.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 22 | 29 | $13,765 | $2,775 | 20.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 60 | 70 | $12,841 | $2,698 | 21.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 33 | 33 | $5,414 | $1,408 | 26.0% |
About Dr. Matthew Davids, M.D
Dr. Matthew Davids, M.D is a Hematology & Oncology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/07/2008. The National Provider Identifier (NPI) number assigned to this provider is 1659541522.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Matthew Davids, M.D has received a total of $808,362 in payments from pharmaceutical and medical device companies, with $101,162 received in 2024. These payments were reported across 504 transactions from 27 companies. The most common payment nature is "Consulting Fee" ($625,943).
As a Medicare-enrolled provider, Davids has provided services to 925 Medicare beneficiaries, totaling 1,220 services with total Medicare billing of $105,104. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Boston, MA
- Active Since 03/07/2008
- Last Updated 04/12/2011
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1659541522
Products in Payments
- VENCLEXTA (Drug) $76,395
- CALQUENCE (Drug) $70,915
- Venclexta (Drug) $68,034
- BRUKINSA (Drug) $55,973
- IMBRUVICA (Drug) $53,198
- Imbruvica (Drug) $26,689
- COPIKTRA (Drug) $25,000
- clonoSEQ (Device) $22,784
- VENCLEXTA (Biological) $20,382
- Rituxan (Biological) $17,256
- JAYPIRCA (Drug) $11,840
- Copiktra (Drug) $11,827
- Revlimid (Drug) $9,333
- Epkinly (Drug) $8,916
- Non-Covered Product (Drug) $8,780
- HYQVIA (Biological) $6,640
- BRIUMVI (Drug) $6,625
- LUMOXITI (Biological) $4,795
- UKONIQ (Drug) $4,468
- GAZYVA (Biological) $2,310
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Boston
Dr. Julio Hajdenberg, Md, MD
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Eric Jacobsen, Md, MD
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Paul Richardson, Md, MD
Hematology & Oncology — Payments: $920,265
Hematology & Oncology $920,265
David Avigan, M.d, M.D
Hematology & Oncology — Payments: $679,225
Hematology & Oncology $679,225
Anthony Letai, Md, MD
Hematology & Oncology — Payments: $569,795
Hematology & Oncology $569,795
Amir Fathi, M.d, M.D
Hematology & Oncology — Payments: $548,854
Hematology & Oncology $548,854